Press Releases

Quotient Sciences Announces Successful US FDA Inspection of Alnwick, UK Facility

Institute for Myeloma & Bone Cancer Research Announces Publication in Targeted Oncology Longest Survival Reported to Date for Multiple Myeloma Patients

Institute for Myeloma & Bone Cancer Research Announces Publication in Targeted Oncology Longest Survival Reported to Date for Multiple Myeloma Patients WEST HOLLYWOOD, Calif., Sept. 19, 2023 /PRNewswire/ -- The Institute for Myeloma & Bone Cancer Research (IMBCR) announces the publication in Targeted Oncology on the outstanding survival of 161 unselected, new patients with multiple myeloma (MM) who started treatment from 2006 to 2022 at Berenson Cancer Center. In 2023, the American Cancer Society anticipates about 35,730 new cases of MM will be diagnosed (19,860 in men and 15,870 in women). Approximately 12,590 deaths are expected to occur this year (7,000 in men and 5,590 in women). This study shows an average survival of 136.2 months. It is the longest reported in any population of unselected, newly diagnosed multiple myeloma patients. Average survival was even longer (173.5 months) for those younger than 65. While myeloma care centers consider stem cell transplant as the standard first treatment, none of the patients in this clinical setting received a stem cell transplant. James R. Berenson, MD, Medical and Scientific Director of IMBCR, led this team and stated, "Round-the-clock physician access and more frequent monitoring of each patient's status allowing rapid changes in treatments that are either not working or causing unwanted side effects and access to the latest treatments have resulted in these unprecedented outcomes." This comprehensive and personalized approach by a forward-thinking myeloma expert has resulted in publication of the longest survival reported to date. About the Institute for Myeloma & Bone Cancer Research (IMBCR) Founded by Dr. James R. Berenson in 2003, IMBCR is a West Hollywood-based independent non profit cancer research institute dedicated to discovering and developing more effective treatments, and ultimately a cure for myeloma and bone cancer. IMBCR's innovative research provides cancer patients with greater longevity and an improved quality of life. The Institute's multiple myeloma related research is far-reaching and benefits all cancers where bone metastasis is a threat. This includes those with breast cancer, lung cancer, and prostate cancer as well as other types of bone marrow and blood cancer such as lymphoma and leukemia. Because of expanded drug therapy options and treatment combinations, IMBCR provides patients with an opportunity to enhance their chances of surviving cancer and conquer one of the hardest challenges of their lives. These results provide patients, caregivers, and healthcare professionals with a much more optimistic outlook for those dealing with this B-cell malignancy. About Berenson Cancer Center (BCC) Berenson Cancer Center is a comprehensive clinic that has specialized in the treatment of patients with multiple myeloma and related diseases for more than 20 years. James R. Berenson, MD, President, and Medical Director, has been conducting clinical and basic research for over 40 years. He has published nearly 300 peer-reviewed articles. Dr. Berenson has been involved in many of the major breakthroughs that have brought new treatments to patients with these diseases resulting in both an improvement in the length and quality of their lives. About Multiple Myeloma Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system. The immune system is made up of several types of cells that work together to fight infections and other diseases. Lymphocytes (lymph cells) are one of the main types of white blood cells in the immune system and include T cells and B cells. Lymphocytes are in many areas of the body, such as lymph nodes, bone marrow, intestines, and bloodstream. Contact: Jessica Yataco, MBA Chief Operations Officer Institute for Myeloma & Bone Cancer Research jyataco@berensoncancercenter.com

Emmes Acquires VaxTRIALS

Sygnature Discovery collaborates with Axol Bioscience to utilize human iPSC-derived microglial cells in high-content imaging drug discovery screening workflows

Elligo Health Research Announces Expansion of Study Marketplace With Syneos Health

Elligo Health Research®, the largest healthcare-enabling research organization, today announced it is expanding its Study Marketplace platform with Syneos Health, a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success.

Sharp acquires Berkshire Sterile Manufacturing

Veramed expands its global footprint by acquiring Data Management, Biostatistics and Medical Writing services company Clinical Trial Data Services (CTDS)

Specialist Biometrics CRO, Veramed, today announced the acquisition of Boston-based data management, biostatistics and medical writing company, CTDS.

Phastar Net-Zero Target Approved by the Science Based Targets Initiative

Phastar Net-Zero Target Approved by the Science Based Targets Initiative Phastar commits to achieving Net-Zero Standard by 2035

BioIVT Elevates Cell and Gene Therapy to an Artform at Meeting on the Mesa

Expert staff will be on hand at the conference to discuss how BioIVT can support CGT research from discovery and development to commercialization.

BioIVT to Host a Webinar on Optimizing Liquid Biopsy Research

This webinar will discuss the importance of using standardized collection protocols and a diverse donor base to validate biomarkers and ensure their clinical utility.

Takara Bio enters into a license agreement of RetroNectin® with Fondazione Telethon ETS

Takara Bio Inc. has announced that it has entered into a License Agreement with non-profit/charity organization, Telethon.

Emmes Introduces Telehealth Capabilities into Advantage eClinical

Alder Therapeutics set to redefine cell therapy development

Alder Therapeutics is set to reshape the cell therapy sector with a novel, reduced-risk approach to cell therapy development and two promising cell therapy candidates for diseases with high unmet need.

DNAnexus-enabled UK Biobank Research Analysis Platform Surpasses 5,000 Users in Two Years

The DNAnexus-enabled UK Biobank Research Analysis Platform community has grown to more than 5,000 users around the world.

Tower Cold Chain Accelerates Growth with Two New Senior Appointments for The Americas

Following the opening of its new Centre of Excellence facility to support further growth across the Americas, advanced temperature-controlled container specialist, Tower Cold Chain, has continued the expansion of its global team with the appointment of two senior leaders.

X-Chem and Structural Genomics Consortium Enter Into Collaboration to Unlock the Human Proteome and Promote Open Science

X-Chem, a global leader in innovative drug discovery services, and the Structural Genomics Consortium (SGC), a public-private partnership dedicated to accelerating drug discovery through open science, announced that they have entered a collaboration aimed at creating new chemical tools to study human proteins.

Creative Proteomics Leads the Way with Cutting-Edge RNA Pull Down Service

Creative Proteomics Introduces Mature Solutions for Membrane Protein Identification

Evecxia Therapeutics and Quotient Sciences Complete Phase I Clinical Milestone for New Depression Treatment

Creative Proteomics Launches State-of-the-Art Peptide Sequencing Service to Advance Proteomics Research